Use of 2-methylene-19-nor- (20S) -1α, 25-dihydroxyvitamin D3 to treat primary hyperparathyroidism

摘要

Symptoms of primary hyperparathyroidism or primary hyperparathyroidism in subjects in need of administration of 2-methylene-19-nor- (20S) -1α, 25-dihydroxyvitamin D3 (2MD) A method of treating is disclosed. Also disclosed is a method of administering 2MD to prevent symptoms of primary hyperparathyroidism in patients with primary hyperparathyroidism and at risk of developing primary hyperparathyroidism . These methods preferably do not result in elevated serum calcium levels and the development of hypercalcemia in the subject.